Rabbit Polyclonal LAYN Antibody

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Jurkat and K562 cell lysates, Primary antibody: P04068(LAYN Antibody) at dilution 1/700, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 2 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P04068(LAYN Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

LAYN antibody research focuses on Layilin (LAYN), a transmembrane protein identified in the early 2000s as a cell adhesion regulator. Structurally, LAYN contains a carbohydrate-binding domain that interacts with extracellular matrix components like hyaluronan, facilitating cell-matrix communication. It is highly expressed in immune cells, particularly regulatory T cells (Tregs) and exhausted cytotoxic T lymphocytes (CTLs), where it functions as an immune checkpoint modulator.

Studies highlight LAYN's dual role in immunity. In Tregs, it supports immunosuppressive activity, maintaining immune tolerance. Conversely, in tumor-infiltrating CTLs, elevated LAYN correlates with T cell exhaustion, impairing antitumor responses. This positions LAYN as a potential biomarker for dysfunctional T cells in cancers like melanoma and hepatocellular carcinoma. Therapeutic strategies targeting LAYN aim to reverse T cell exhaustion or inhibit Treg-mediated immunosuppression, potentially enhancing cancer immunotherapy efficacy.

Recent investigations also explore LAYN's involvement in autoimmune diseases and chronic inflammation, broadening its clinical relevance. Despite progress, mechanisms underlying LAYN's signaling and tissue-specific functions remain partially unclear, driving ongoing research to refine its therapeutic targeting. Overall, LAYN antibodies represent a promising tool for deciphering immune regulation and developing next-generation immunotherapies.